Biosensor for on-site measurement of hexanal in food
An innovative biosensor utilizing genetically engineered flagellin proteins to detect hexanal in food, enhancing quality and safety. Compatible with commercial potentiostats, it offers precise and sensitive on-site measurements.
Overview
The proposed biosensor offers a cutting-edge solution for the on-site measurement of hexanal in food products, notably enhancing quality control and safety in the food industry. By leveraging genetically modified flagellin proteins that specifically bind to hexanal, the sensor provides a high density of binding sites for accurate detection. This innovative technology allows for simple droplet measurement compatible with existing commercial potentiostats, making it accessible for widespread applications.
Technical specifications
The core technology involves a genetically engineered protein that binds hexanal, forming stable polymers that constitute the biosensor's sensing layer. Key features include:
- High binding site density: Up to tens of thousands of sites per fibre, ensuring sensitivity and a broad linear signal range.
- Compatibility: Designed to work with commercially available potentiostats for straightforward implementation.
- Robustness: Utilizes self-assembling flagellin proteins known for their stability and previous successful application in nickel ion detection.
The development process includes designing hexanal binding motifs, recombinant DNA work for protein production, and optimization of sensor performance, ensuring reliability and efficiency.
Technology readiness level
This technology is currently at TRL 4, indicating that the biosensor components and prototypes have been validated in laboratory settings. Future steps include optimization of protein production and purification, sensor stability and specificity studies, and real-world verification of sensor performance, paving the way for potential commercialization.
About iPASy Technologies
iPASy Technologies is a Veszprém-based medical technology startup established in 2023 that focuses on advancing prostate cancer diagnostics. The company has developed a non-invasive, urine-based diagnostic procedure that utilizes advanced PSA glycosylation pattern analysis. This method is designed to improve diagnostic accuracy, reduce false-positive rates compared to conventional serum PSA tests, and decrease the necessity for unnecessary biopsies. The technology is supported by research originating from a Ph.D. program and has reached the preliminary examination stage of patent application, with clinical trials initiated in Germany.
By providing a more reliable and cost-effective screening solution, iPASy Technologies aims to redefine the standard of care for prostate cancer diagnostics. The startup, which employs a small team, is actively working toward CE marking for its diagnostic kit to streamline the screening process and offer more comprehensive clinical insights. The company has showcased its developments at international industry events, such as MEDICA, to engage with partners and medical professionals in the field of clinical diagnostics.
Inquire about this partnering listing
Industry applications
delivered to your inbox.